Dr Maria C. M. Orr – Executive Director, Personalised Healthcare and Biomarkers, AstraZeneca
Maria Orr graduated from Trinity College, Dublin and completed a PhD in molecular genetics at Sheffield University. Following a brief period in academia, Maria moved into the pharmaceutical industry in 1994 where she has been actively involved in the application of genetics to drive drug discovery & development.
Maria joined the oncology therapeutic area of AstraZeneca (AZ) in 2005 where she championed of the use of biomarkers to aid clinical drug development, focusing primarily on the use of biomarkers to drive patient segmentation. In 2010 she joined the newly formed Personalised Healthcare & Biomarkers (PHB) function of AZ where she successfully led the team delivering the companion diagnostic for the PARP inhibitor Lynparza (olaparib).
In April 2016 Maria moved to a Franchise Leader position in Precision Medicine and Genomics (PMG) where she oversees the delivery of companion diagnostics for the DNA Damage Response and EGFR portfolios for oncology including the companion diagnostics for Lynparza (olaparib), Tagrisso (osimertinib) and Iressa (gefitinib). Most recently Maria was appointed Head of Companion Diagnostic Development for the early oncology portfolio in AstraZeneca.